Dried Urine Spots Detect Cytomegalovirus in Newborns
|
By LabMedica International staff writers Posted on 21 Jun 2012 |
Dried urine spots (DUS) can be used to provide a simple screening tool for congenital Cytomegalovirus (CMV) infection in newborn infants.
A standardized method for CMV quantification from DUS has been developed that uses molecular technology to detect and quantify the viral load in urinary samples.
Scientists at Johns Hopkins Medical Institutions (Baltimore, MD, USA) collected and tested archived urine samples from 27 congenitally infected and 15 uninfected neonates. DNA was extracted using an automated method from urine samples placed on filter paper discs. A quantitative CMV real-time polymerase chain reaction (rt-PCR) assay was performed on the extracted DNA, spiked urine samples, and suitable control samples.
Urine samples from congenitally infected newborns and negative controls either were diluted 1:10 or applied on filter paper at the same volume. The analytical sensitivity was determined of 100% of replicates at 7,500 CMV copies/mL. The actual detection limit was 22 DNA copies/disc. DNA copy number from DUS correlated well with copy number from 1:10 diluted urine, although there was a trend for lower levels from DUS. Amplification was performed on a 7500 Real-Time PCR System (Applied Biosystems; Foster City, CA, USA).
Concentrations of CMV DNA in the 27 positive samples ranged from 4.4 to 8.8 log10 copies/mL, with a mean of 6.5 log10 copies/mL. Three samples had CMV DNA levels that were greater than the highest concentration of the spikes urine tested for measurable range calculation. This screening method could be used to detect the presence of congenital CMV infection by inserting a filter paper in the newborn's diaper and therefore for this purpose, quantification may not be necessary.
The authors concluded that the assay may provide a simple and rapid tool for CMV detection and quantification from DUS in underdeveloped or developing countries in which diagnostic capabilities for CMV are lacking. Information on CMV prevalence from resource-constrained areas is currently limited due to lack of diagnostic infrastructure. The study was published on June 1, 2012, in the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
Johns Hopkins Medical Institutions
Applied Biosystems
A standardized method for CMV quantification from DUS has been developed that uses molecular technology to detect and quantify the viral load in urinary samples.
Scientists at Johns Hopkins Medical Institutions (Baltimore, MD, USA) collected and tested archived urine samples from 27 congenitally infected and 15 uninfected neonates. DNA was extracted using an automated method from urine samples placed on filter paper discs. A quantitative CMV real-time polymerase chain reaction (rt-PCR) assay was performed on the extracted DNA, spiked urine samples, and suitable control samples.
Urine samples from congenitally infected newborns and negative controls either were diluted 1:10 or applied on filter paper at the same volume. The analytical sensitivity was determined of 100% of replicates at 7,500 CMV copies/mL. The actual detection limit was 22 DNA copies/disc. DNA copy number from DUS correlated well with copy number from 1:10 diluted urine, although there was a trend for lower levels from DUS. Amplification was performed on a 7500 Real-Time PCR System (Applied Biosystems; Foster City, CA, USA).
Concentrations of CMV DNA in the 27 positive samples ranged from 4.4 to 8.8 log10 copies/mL, with a mean of 6.5 log10 copies/mL. Three samples had CMV DNA levels that were greater than the highest concentration of the spikes urine tested for measurable range calculation. This screening method could be used to detect the presence of congenital CMV infection by inserting a filter paper in the newborn's diaper and therefore for this purpose, quantification may not be necessary.
The authors concluded that the assay may provide a simple and rapid tool for CMV detection and quantification from DUS in underdeveloped or developing countries in which diagnostic capabilities for CMV are lacking. Information on CMV prevalence from resource-constrained areas is currently limited due to lack of diagnostic infrastructure. The study was published on June 1, 2012, in the journal Diagnostic Microbiology and Infectious Disease.
Related Links:
Johns Hopkins Medical Institutions
Applied Biosystems
Latest Molecular Diagnostics News
- Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
- New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
- Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read more
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








